A clearly defined, sensible mechanism of action is helping to make up for a gaping hole in the PCSK9 inhibitors’ otherwise stellar resume – that is, a proven benefit for reduction in cardiovascular events in well-designed, long-term outcomes trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?